Serological follow up of positive SARS-CoV-2 cases

Salud Publica Mex. 2022 Jun 2;64(3, may-jun):243-248. doi: 10.21149/13065.

Abstract

Objective: To describe the humoral response in a cohort with mild and asymptomatic SARS-CoV-2 infection previ-ously identified in a community-based serological survey.

Materials and methods: This study was an observational follow up of 193 subjects previously identified with positive anti-SARS-CoV-2 antibodies invited for a second test 112 days after the first sampling. All completed a standardized electronic questionnaire. IgM/IgG antibodies were determined using a qualitative IgM/IgG chemiluminescent immunoassay.

Results: Among the 193 eligible subjects, a total of 174 (90%) attended the follow-up visit, and their serum samples were tested. Of the samples, 171 (98.3%) were still positive, and 3 (1.7%) were negative. Also, the cut-off index (COI) value of the immunoassay significantly increased from the first to the second test (P <0.001).

Conclusions: Our findings support a sustained humoral response in individuals with mild and asymptomatic SARS-CoV-2 infection up to 112 days after a positive serologic baseline test, accompanied by increasing antibody titers.

Publication types

  • Observational Study

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G
  • Immunoglobulin M
  • SARS-CoV-2*

Substances

  • Antibodies, Viral
  • Immunoglobulin G
  • Immunoglobulin M